NCT03102021View on ClinicalTrials.gov

The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Acute Kidney Injury
Interventions
DRUG

erythropoietin

500 units/kg daily for 3 days at onset of acute kidney injury

DRUG

saline

saline 10 ml for 3 days

Trial Locations (1)

75216

Dallas VAMC, Dallas

All Listed Sponsors
lead

North Texas Veterans Healthcare System

FED

NCT03102021 - The Effect of Human Recombinant Erythropoietin in Acute Renal Failure | Biotech Hunter | Biotech Hunter